TrialArthritis research & therapy2016

Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.

Anita Boyapati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.